Alcon
ALC NYSE· Health Care Supplies
Last close · Oct 26, 2026
$69.99
KIRA · Stoqly’s AI analyst, in plain words
- Alcon had $10.4B of revenue in fiscal 2025, up 4.9% on the year before. Over five years, revenue changed +8.8% a year on average.
- Its operating margin was 13.1%, down 1.2 pts: of every 100 in sales, about 13 is left after running the business.
- Alcon made $980M of net profit in fiscal 2025. From fiscal 2010 to 2025, diluted EPS grew −13.5% a year.
- Free cash flow was $1.7B in fiscal 2025, 16.6% of revenue.
- Alcon returned $842M to shareholders in fiscal 2025, 49% of free cash flow. The diluted share count fell 0.3%.
- Alcon owes $3.2B more than it holds in cash.
Market cap
$34.7B
P/E
—
Revenue
$10.4B
Net income
$980M
Free cash flow
$1.7B
Operating margin
13.1%
Alcon in 30 seconds · fiscal 2025
Are sales growing?
+4.9%
Only a little. Sales grew 4.9% last year.
Does it make a profit?
9.4%
A little. It keeps 9.4% of every sale as profit.
Does profit turn into cash?
16.6%
Yes. 16.6% of sales ends up as free cash.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
What Alcon does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Feb 24, 2026
- Legal name
- Alcon Inc.
- CIK
- 0001167379
Alcon · ALC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $8.3B | $8.7B | $9.5B | $9.9B | $10.4B |
| Revenue growth | 21.3% | 5.1% | 8.5% | 4.8% | 4.9% |
| Gross margin | 56.1% | 54.5% | 55.5% | 55.6% | 55.2% |
| Operating margin | 7.0% | 7.7% | 11.0% | 14.3% | 13.1% |
| Net income | $376M | $335M | $974M | $1.0B | $980M |
| Net margin | 4.5% | 3.8% | 10.3% | 10.3% | 9.4% |
| Diluted EPS | $0.76 | $0.68 | $1.96 | $2.05 | $1.98 |
| Cash | |||||
| Cash from operations | $1.3B | $1.2B | $1.4B | $2.1B | $2.3B |
| Capital expenditure | $700M | $636M | $658M | $473M | $543M |
| Free cash flow | $645M | $581M | $730M | $1.6B | $1.7B |
| FCF margin | 7.8% | 6.7% | 7.7% | 16.2% | 16.6% |
| Dividends paid | $54.0M | $100M | $116M | $130M | $166M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $676M |
| Share count change | 0.9% | 0.2% | 0.4% | 0.2% | −0.3% |
| Debt and strength | |||||
| Cash and short-term investments | $1.6B | $980M | $1.1B | $1.7B | $1.5B |
| Debt incl. finance leases | $4.1B | $4.6B | $4.7B | $4.6B | $4.7B |
| Shareholders' equity | $19.3B | $19.7B | $20.6B | $21.6B | $22.0B |
| Current ratio | 2.2x | 1.9x | 2.4x | 2.8x | 2.1x |
| Interest coverage | 4.8x | 5.0x | 5.5x | 7.4x | 6.7x |
| Returns and quality | |||||
| Return on capital | 2.4% | 2.2% | 4.4% | 4.7% | 4.6% |
| Return on equity | 2.0% | 1.7% | 4.8% | 4.8% | 4.5% |
| Piotroski F-score | 7 | 4 | 8 | 8 | 6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Alcon · ALC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Alcon ALC | $34.7B | 4.9% | 13.1% | 16.6% | 4.6% | — | 6 |
| Cooper Companies COO | $11.8B | 5.1% | 16.7% | 10.6% | 4.3% | 20.9x | 5 |
| Align Technology ALGN | $10.9B | 0.9% | 13.5% | 12.2% | 13.3% | 26.5x | 5 |
| Dentsply Sirona XRAY | $1.8B | −3.0% | −11.5% | 2.8% | −9.9% | — | 6 |
| West Pharmaceutical Services WST | $28.1B | 6.3% | 19.0% | 15.3% | 18.7% | 50.5x | 9 |
KIRA
At $69.99 a share, the company is worth $34.7B.
Alcon grew sales faster than 2 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001167379). Data updated October 23, 2026. For information only — not investment advice. Check the original filings before relying on any figure.